Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer

  • Technology appraisal guidance
  • TA1110
  • Published: 

History

Documents created during the development process.

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6378